US 12,268,753 B2
Nanomaterials comprising a biodegradable feature
Mina Fawzy Shehata, Spartanburg, SC (US); Neeraj Narendra Patwardhan, Medford, MA (US); Gregory Lawrence Hamilton, Atlanta, GA (US); Cory Dane Sago, Boston, MA (US); and Milloni Balwantkumar Chhabra, Dunwoody, GA (US)
Assigned to Beam Therapeutics Inc., Cambridge, MA (US)
Filed by Beam Therapeutics Inc., Cambridge, MA (US)
Filed on Jan. 19, 2022, as Appl. No. 17/579,150.
Claims priority of provisional application 63/139,731, filed on Jan. 20, 2021.
Prior Publication US 2022/0249694 A1, Aug. 11, 2022
Int. Cl. C07C 219/16 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); A61P 1/16 (2006.01); C07D 207/08 (2006.01); C07D 207/16 (2006.01); C07D 211/22 (2006.01); C07D 211/62 (2006.01); C07D 295/15 (2006.01); C07J 41/00 (2006.01)
CPC A61K 47/6929 (2017.08) [A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61P 1/16 (2018.01); C07C 219/16 (2013.01); C07D 211/22 (2013.01)] 14 Claims
 
1. A compound of Formula (IIIA):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
L2 is a covalent bond, an optionally substituted bivalent saturated or unsaturated, straight or branched C1-C12 hydrocarbon chain, or

OG Complex Work Unit Chemistry
CyA is an optionally substituted ring selected from phenylene and 3- to 7-membered saturated or partially unsaturated carbocyclene;
each m is independently 0, 1, or 2;
R1 is a saturated, branched C3-C20 hydrocarbon chain;
each L4 is independently a bivalent saturated or unsaturated, straight or branched C1-C6 hydrocarbon chain;
each A1 and A2 is independently C2-C20 alkenyl;
X1 is a covalent bond, —O—, or —NR—;
—X2—X3 is selected from:

OG Complex Work Unit Chemistry